Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
David MoadelTue, October 6, 2026 at 7:03 PM UTC
0
Maddie Meyer / Getty Images News via Getty ImagesQuick Read -
Moderna stock has surged 546% in 2026 and is joining the NASDAQ 100, but the rally may already price in its oncology pipeline potential.
BioNTech shares the same mRNA platform but is nearly flat for 2026, while Pfizer is up just 16%, underscoring Moderna's product-specific premium.
Building a portfolio and living off one are two completely different skills, and almost nobody teaches the second. This problem is what The Definitive Guide to Retirement Income helps, and it is free today. Read more here. (Sponsor)
Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA), and the size of that run now raises a hard question about what comes next. Moderna stock is up 545% year-to-date to $190.27, believe it or not. That figure leaves shareholders deciding whether to lock in their gains or lean further into the story.
MRNA Price Target — 24/7 Wall St.
For its part, Pfizer (NYSE:PFE) stock is up 16% year-to-date at $27.40, a healthy gain for a vaccine seller with a much broader drug lineup. Meanwhile, BioNTech (NASDAQ:BNTX) stock has gained 1% year-to-date at $96.19, leaving the other listed messenger RNA (mRNA) developer close to flat while Moderna stock has multiplied several times over, according to Reuters.
Sector gains look modest beside that surge, with the iShares Biotechnology ETF (NASDAQ:IBB) up 21% year-to-date, according to Reuters. For a broader market gauge, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) has advanced 14% year-to-date, trailing even the biotech fund. Those gaps frame the rally in Moderna stock as a company story.
Need-to-Know Developments for Moderna
Reuters reported last week that Moderna is set to join the NASDAQ 100, replacing Warner Bros Discovery. Index inclusion changes which funds must own Moderna stock, and that shift in the buyer base can draw fresh attention to the company. A NASDAQ 100 slot also places Moderna among the largest nonfinancial companies listed on Nasdaq, a marker of how much the market's view of the company has changed.
Now Available: The Definitive Guide to Retirement Income
Many successful investors eventually reach the same moment. The saving is done, the portfolio is built, and the question quietly changes from how much can I grow this to how much can I take out? Get that second question wrong and decades of good investing can come apart in a handful of years.
That is exactly what The Definitive Guide to Retirement Income helps answer. It covers what your retirement could actually cost, which income sources are worth using, and the withdrawal math that decides whether the money lasts. It is free today from Fisher Investments. Read More Here ›
Advertisement
Moderna sells four approved products: Spikevax for COVID-19, mRESVIA for respiratory syncytial virus, mNEXSPIKE as a next-generation COVID vaccine and mCOMBRIAX as a combination influenza and COVID vaccine, according to Reuters. Underneath every product sits the company's mRNA platform, which Moderna sells as its advantage because the same technology can be pointed at a new target quickly.
BioNTech works on the same underlying technology, which makes BioNTech the closest comparison to Moderna among the three companies, and its shares sit close to flat for the year, so platform enthusiasm alone hasn't lifted every mRNA name. The difference suggests the market is paid back the specific products and pipeline at Moderna over the shared science.
Pipeline Promise Meets a Steep Price
Moderna's bull case rests on the company's oncology pipeline, including intismeran autogene, a personalized cancer vaccine developed in collaboration with Merck. A personalized cancer vaccine would reach a market Moderna's respiratory franchise never could, and the company's pipeline also extends into rare disease. Four approved products already give Moderna a commercial base while that oncology work develops.
MRNA Price Scenario — 24/7 Wall St.
However, the 545% advance in Moderna stock has already priced in a great deal of what the company's pipeline might eventually deliver (riding a run like this is fine as long as the exit is planned, which is the whole point of our free bubble handbook). Index membership changes the buyer base for Moderna stock, while the company's scientific case still depends on what its programs prove. It will be worth watching whether MRNA stock holds its gains once the index change takes effect.
Given how far Moderna stock has run ahead of BioNTech stock, Pfizer stock and the biotech fund, investors should adjust their holdings carefully. Investors should size their positions to reflect the gap between the 545% gain in MRNA stock and what the company's pipeline has proved so far.
Released: The Definitive Guide to Retirement Income
(Sponsor) Most people spend their entire working lives focusing on one thing: growing a pile of money. Then they retire and discover the skill they actually need is close to the opposite. Turning that pile into steady income, year after year, through good markets and bad, without ever running out.
It may be the least discussed and most consequential transition in personal finance, and plenty of otherwise careful investors walk into it with no real plan. That is exactly what The Definitive Guide to Retirement Income helps answer. It is a free guide from Fisher Investments covering what your retirement will really cost, where the cash flow should come from, and how much you can safely withdraw each year. Learn more here. Learn More Here ›
Contact editorial@247wallst.com for any questions or corrections.
Source: “AOL Money”
